Literature DB >> 3052913

Current therapy of the failing heart.

J N Cohn1.   

Abstract

Myocardial dysfunction eventuating in systolic and diastolic pump function abnormalities is a consequence of a wide variety of cardiac diseases. The symptoms that develop in this syndrome appear to be related as much to peripheral and neurohormonal mechanisms as to the underlying pathological and cardiac functional abnormality. Relief of symptoms, slowing of the progression of the cardiac functional abnormality, and prolongation of life provide the major agenda for the physician faced with the management of these patients. Judicious use of vasodilators, diuretics, digoxin, dietary therapy, and exercise therapy can relieve symptoms and improve the quality of life in most patients suffering from this syndrome. Recent evidence that vasodilator drugs can prolong life now provides the physician with further justification for routine use of this class of compounds. The eventual solution to the high mortality in this common disease process may be prevention of the development of overt heart failure by more prompt recognition and early treatment of the signs of ventricular dysfunction. This possibility must await the completion of current and proposed clinical trials.

Entities:  

Mesh:

Year:  1988        PMID: 3052913     DOI: 10.1161/01.cir.78.5.1099

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Cardiovascular effects of alcohol.

Authors:  D M Davidson
Journal:  West J Med       Date:  1989-10

2.  [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].

Authors:  P K Schädlich; B Paschen; J G Brecht
Journal:  Med Klin (Munich)       Date:  1997-08-15

3.  How do changes in lifestyle complement medical treatment in heart failure?

Authors:  J Soler-Soler; G Permanyer-Miralda
Journal:  Br Heart J       Date:  1994-09

Review 4.  New drug approaches to the treatment of heart failure in infants and children.

Authors:  S Kaplan
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 5.  Left ventricular dilatation and failure post-myocardial infarction: pathophysiology and possible pharmacologic interventions.

Authors:  B G Firth; P M Dunnmon
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

6.  Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.

Authors:  S Sasayama; H Asanoi; Y Kihara; S Yokawa; Y Terada; S Yoshida; M Ejiri; I Horikoshi
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

Review 7.  Therapeutic management of dilated cardiomyopathy.

Authors:  Y Koga; H Toshima; M Tanaka; K Kajiyama
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 8.  Real-Time Remote Health-Monitoring Systems in a Medical Centre: A Review of the Provision of Healthcare Services-Based Body Sensor Information, Open Challenges and Methodological Aspects.

Authors:  O S Albahri; A A Zaidan; B B Zaidan; M Hashim; A S Albahri; M A Alsalem
Journal:  J Med Syst       Date:  2018-07-25       Impact factor: 4.460

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.